Wearable Large Volume Injectors Hold Promise for Success in Commercialization of Biologics

Authors

  • Michael D. Hooven Enable Injections Inc.
  • Jeannie Joughin

DOI:

https://doi.org/10.5912/jcb805

Keywords:

Large volume wearable injectors, combination products, biologics, drug delivery, cancer, autoimmune diseases, viscosity, formulation, rare diseases, self-administration, subcutaneous injections, patient-centricity

Abstract

With so many biologics in development and no patient-centric way to deliver them, it was inevitable that innovative delivery solutions would emerge that enable a new pharmaceutical product to meet two top criteria for successful commercialization: satisfy patient demands for easy drug administration without disruption to their everyday lives, and address health system demands for lower costs and more value. The solution lies in combining biologic drugs with the more advanced large volume wearable injectors to enable patients to self-inject even the most viscous formulations and volumes of up to 50 mL with ease and comfort in their homes or workplaces.

 

Author Biography

Michael D. Hooven, Enable Injections Inc.

Author Michael D. Hooven:

Michael D. Hooven, President and CEO of Enable Injections, Inc. is an acknowledged industry expert on wearable large volume drug delivery technology. The founder of five medical device companies, he has more than 30 years of experience in the medical device industry in a broad variety of technical and clinical areas. Prior to founding AtriCure (NASDAQ:ATRC) and Enable Medical, Mike  headed all internal product development at Ethicon Endo-Surgery and held Engineering positions at Siemens/Pacesetter and at Cordis Corporation. He earned a Bachelor of Science in Physics and a Master of Science in Mechanical Engineering from the University of Michigan.

 

References

Pharmaceutical companies to accelerate investment in patient-centric capabilities and services over next two years, according to Accenture report [press release]. Published April 12, 2016. https://newsroom.accenture.com/news/pharmaceutical-companiesto-accelerate-investment-in-patient-centric-capabilities-and-services-over-next-two-yearsaccording-to-accenture-report.htm.

Bolus Injectors Market, 2014-2024, November 2013 – Roots Analysis Private Ltd

Medicines in development – Biologics http://pharma.org/sites/default/files/pdf/biologics2013.pdf

D. Gilbert and & D. Cothran, "SC versus IV Delivery: Reducing Costs while Increasing Patient Satisfaction," Hematology & Oncology News & Issues, Dec. 25–27, 2005

J. Prettyman, "Subcutaneous or Intramuscular? Confronting a Parenteral Administration Dilemma," Medsurg. Nursing, 14 (2), 93–98 (2005).

H.C. Ansel, L.V. Allen, and N.G. Popovich, Pharmaceutical Dosage Forms and Drug Delivery Systems (Lippincott Williams & Wilkins, Philadelphia, PA, 8th ed., 2004).

Collins, M. “Here’s What’s Important About Alder Biopharmaceuticals’ Latest Release”. Market Exclusive, July 26, 2016

Burgess, BE, “Optimizing Drug Delivery for Modern Biologics”. BioPharm Int, 2012, Vol 25 (5).

Doughty D, Clawson CZ, Lamber W, et al., “Understanding subcutaneous tissue pressure for engineering injection devices for large-volume protein delivery.” J Pharm Sci, 2016, Vol 105, pp 2105-2113.

Rule S et al. “Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom”. J Med Econ, 2014, Vol 17(7), pp 459-468.

Škalko-Basnet N, “Biologics: the role of delivery systems in improved therapy”, Biologics, 2014, Vol 8, pp 107-114.

Palm T, Sahin E, Gandi R, et al, “The Importance of the Concentration-Temperature-Viscosity Relationship for the Development of Biologics”, BioProcess Int, March 10, 2015.

Published

2017-07-01

Issue

Section

Articles